Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. - Wikidata - awgldk - TriplyDB

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

http://www.wikidata.org/entity/Q37635011

about

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development Therapeutic aptamers: developmental potential as anticancer drugs Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics Application of quantitative pharmacology in development of therapeutic monoclonal antibodies Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats.Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis.The development of potential antibody-based therapies for myeloma Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.Misdiagnosis of late-onset Lyme arthritis by inappropriate use of Borrelia burgdorferi immunoblot testing with synovial fluid Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.Monoclonal antibody therapy for Junin virus infection.The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice.Engineering the variable region of therapeutic IgG antibodies.Targeted drug delivery for cancer therapy: the other side of antibodies.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Impact of physiochemical properties on pharmacokinetics of protein therapeutics.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Review on modeling anti-antibody responses to monoclonal antibodies.Assessments of antibody biodistribution.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Long-term direct visualization of passively transferred fluorophore-conjugated antibodies.Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.

P2860

Q28082880-322C9A35-C1FF-488D-B1F9-D7FCB96F9F01 Q28084276-684DF99F-1482-467A-89EF-32A3D47DCC21 Q28085157-918D8430-38A3-43C4-9410-F8DFFE09F9B9 Q28478679-831FA260-127F-45F5-B2C5-9422AA6F9475 Q28543591-F37DAB2C-EA27-44B4-98DA-ECB1A7F92E7A Q33405623-719B3CB3-D192-484F-9047-B6DC3CB0E738 Q33838871-A05359E3-6610-4D47-BE77-715ACC10A9A8 Q34275537-BF7A31C2-D78B-4A88-BC6C-7847F51B1553 Q34293689-ACDE4EE8-4912-41FD-8F65-A0FF7AAC5524 Q35036388-FC1D45F9-519D-4DE5-8CE5-ABF881802355 Q35600264-7BE67A2A-0964-4365-83CA-C9F652C5CF6B Q35768430-B343967D-B3AC-465B-9833-819A3964BA01 Q35768564-E782D038-12D1-4F96-80FB-2E2F3C03A568 Q35788245-582C7F23-81CF-4094-B6B8-DD8E1A72291C Q35879455-33153D40-58D3-45AC-917C-79976AC52681 Q36153295-8DB6ECB3-98B7-4C80-8FCF-E498D5567D9B Q36211427-DF4F2DB6-EFC4-4376-BC3B-1E0B220ADBF3 Q36269285-68308BC2-B589-482F-A0D7-BB01C91C56F9 Q36378636-C085A5EE-4207-4BED-8AD0-717AA8E018FD Q36444225-7299EAB0-B57E-4E0C-8B92-44C4EA64590B Q36752488-54C8267F-A334-47AD-BD7A-9E2CEEF0750D Q36831453-EB82C0D6-7A51-46A2-AD82-07760E2E56CA Q37327307-5DC598B8-6C27-4ADF-9279-A358863DDC3B Q37331009-39E3861A-F7DD-4EE1-B0A5-7161AB8F31CF Q37561560-1F292130-66AE-42D4-9D54-CC37370A5D2C Q37719087-3D45DE23-3AD3-42A2-86D8-35D033D4F359 Q37853324-44DF27A4-5E01-4A59-817B-EBDAC67F3BF6 Q38058816-52AE33E4-34E1-4FC5-9E22-6978EC2BED2C Q38072598-51225889-9133-4F28-958F-033043564884 Q38098934-7896C001-FB66-4034-934A-15CBEE6DCE76 Q38176154-B5ED010A-C1F4-4A8F-82C8-44FCA00B855C Q38229813-D31A05F0-9DD2-4F80-A170-9FAB2B58D5DF Q38364460-AF68D6DB-90E0-4AA1-BEED-C1BFC5E602A9 Q38501680-4B8F9053-5F7C-460A-9604-E1769366F8E2 Q38540353-CCCEA99A-9F68-4EB6-95D7-95EB34BA7E8D Q38587550-44C80586-FCA6-4476-B340-D638C6855C2B Q38646491-9E02AA22-BE6D-4A2F-8A95-EDF484E58E14 Q38691472-2F01D9FC-FEA7-4174-8882-37D4980BC1EA Q38714339-8F976A4D-352F-4DC2-9599-B886E8E878C7 Q38722944-7931DB3B-33C4-4B17-9C82-1F18E04F6FE9

P2860

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

http://www.wikidata.org/entity/Q37635011

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@en

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@nl

type

label

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@en

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@nl

prefLabel

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@en

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@nl

P1433

Q37635011-0645CC39-9D8C-402C-AE72-9C4E1B5297B3

P1476

Q37635011-636BFFF6-553F-4C86-B5A0-E767B384B7B6

P2093

Q37635011-28B0B60A-E3A9-4A9E-9AA0-2140554C8B75

Q37635011-6A19A5A5-80C6-49D9-922C-120B5AAF7658

Q37635011-E36FD67B-CD87-43D0-9484-5993D16EB81A

P2860

Q37635011-0110C63F-71A4-4C2A-9347-6238C5BA72A6

Q37635011-0152FCFE-963E-46DA-A017-67B00FCA6A9F

Q37635011-04F5E003-6B93-4A2D-94AB-2EF5522D1524

Q37635011-0627C7F8-229D-413D-BD17-0335EF87ABB3

Q37635011-07E0FE36-785A-4F08-891D-36735788AE74

Q37635011-09EBF398-3D85-4185-9204-B8621C48CE2C

Q37635011-11D2A73C-4390-44C9-A943-62EEED6CAF3C

Q37635011-140F372D-A34E-4BCA-98D6-60AD51DE4600

Q37635011-14391A08-31B6-4E8F-9DF1-559E3996BDF3

Q37635011-1D2E2936-74A5-469E-9EA9-A01BC0657563

P2888

Q37635011-16B13F38-11A3-489E-8387-60343BDECAAD

P304

Q37635011-30B2FA27-81CD-478F-B6BB-3D61B0C514FF

P31

Q37635011-779E88FB-65C2-46D8-A498-FE3AD5F54996

P356

Q37635011-225B16D8-7708-409C-8FD5-6542E322A0F9

P407

Q37635011-828F7275-157F-4AAF-B22D-E8BE7C4589FB

P433

Q37635011-4E56A56A-07D7-43AC-B9CB-3A84073B33E0

P478

Q37635011-C307D86B-B2C8-4C3F-A6E7-42EED77EA293

P577

Q37635011-CD965C00-0BF1-4D8B-A872-4C27751042B0

P5875

Q37635011-EAEC4AB6-8EA1-40F3-A57B-E45E11F39D4C

P698

Q37635011-A141B73B-7DD5-4B60-B4B8-6D5601659D58

P921

Q37635011-47CEB1F1-C406-44B0-B7F4-9C3E77B12B6B

P932

Q37635011-BE7793F7-2FBE-4F06-83A4-36B4E81AE198

P356

S12248-009-9157-5

P1433

The AAPS Journal

P1476

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

@en

P2093

Gadi Gazit Bornstein

http://www.w3.org/2001/XMLSchema#string

Hamza Suria

http://www.w3.org/2001/XMLSchema#string

Mohammad Tabrizi

http://www.w3.org/2001/XMLSchema#string

P2860

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

Affinity and avidity in antibody-based tumor targeting

Openings between defective endothelial cells explain tumor vessel leakiness

Angiogenesis in cancer and other diseases

The pharmacological basis of anti-IgE therapy

Human antibody-Fc receptor interactions illuminated by crystal structures

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Why do cancers have high aerobic glycolysis?

Fcgamma receptors: old friends and new family members

Elimination mechanisms of therapeutic monoclonal antibodies

P2888

s12248-009-9157-5

P304

33-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-009-9157-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38100273

http://www.w3.org/2001/XMLSchema#string

P698

19924542

http://www.w3.org/2001/XMLSchema#string

P921

P932

2811642

http://www.w3.org/2001/XMLSchema#string